search icon
gyre-img

Gyre Therapeutics Inc., Common Stock

GYRE

NAQ

$8.68

-$2.53

(-22.57%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$999.95M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
560.5
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.11M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.11 L
$19 H
$8.68

About Gyre Therapeutics Inc., Common Stock

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGYRESectorS&P500
1-Week Return-23.52%-1.91%-1.87%
1-Month Return-5.55%-3.82%8.93%
3-Month Return-17.73%-11.56%-2.39%
6-Month Return-25.37%-10.21%-2.41%
1-Year Return-31.17%-9.91%10.88%
3-Year Return-54.44%-0.28%46.93%
5-Year Return-92.56%31.29%94.89%
10-Year Return-99.8%75.9%177.5%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue20.95M7.34M794.00K113.45M105.76M[{"date":"2020-12-31","value":18.46,"profit":true},{"date":"2021-12-31","value":6.47,"profit":true},{"date":"2022-12-31","value":0.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.22,"profit":true}]
Cost of Revenue9.16M7.38M798.00K4.64M3.88M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":80.54,"profit":true},{"date":"2022-12-31","value":8.71,"profit":true},{"date":"2023-12-31","value":50.59,"profit":true},{"date":"2024-12-31","value":42.39,"profit":true}]
Gross Profit11.79M(42.00K)(4.00K)108.81M101.87M[{"date":"2020-12-31","value":10.83,"profit":true},{"date":"2021-12-31","value":-0.04,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.62,"profit":true}]
Gross Margin56.26%(0.57%)(0.50%)95.91%96.33%[{"date":"2020-12-31","value":58.4,"profit":true},{"date":"2021-12-31","value":-0.59,"profit":false},{"date":"2022-12-31","value":-0.52,"profit":false},{"date":"2023-12-31","value":99.57,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses69.16M87.85M30.40M176.04M85.71M[{"date":"2020-12-31","value":39.28,"profit":true},{"date":"2021-12-31","value":49.9,"profit":true},{"date":"2022-12-31","value":17.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":48.69,"profit":true}]
Operating Income(57.37M)(87.89M)(8.61M)(67.23M)16.16M[{"date":"2020-12-31","value":-354.95,"profit":false},{"date":"2021-12-31","value":-543.8,"profit":false},{"date":"2022-12-31","value":-53.28,"profit":false},{"date":"2023-12-31","value":-415.95,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense-220.96K935.00K(8.69M)8.60M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":2.57,"profit":true},{"date":"2022-12-31","value":10.87,"profit":true},{"date":"2023-12-31","value":-101.03,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(56.24M)(87.93M)(7.89M)(76.97M)23.22M[{"date":"2020-12-31","value":-242.23,"profit":false},{"date":"2021-12-31","value":-378.73,"profit":false},{"date":"2022-12-31","value":-34,"profit":false},{"date":"2023-12-31","value":-331.49,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes(699.00K)(39.00K)348.00K8.52M5.32M[{"date":"2020-12-31","value":-8.21,"profit":false},{"date":"2021-12-31","value":-0.46,"profit":false},{"date":"2022-12-31","value":4.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":62.48,"profit":true}]
Income After Taxes-(87.89M)(8.24M)(85.48M)17.90M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-491.08,"profit":false},{"date":"2022-12-31","value":-46.05,"profit":false},{"date":"2023-12-31","value":-477.6,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations-23.44M4.31M(85.48M)17.90M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":18.41,"profit":true},{"date":"2023-12-31","value":-364.73,"profit":false},{"date":"2024-12-31","value":76.37,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(55.54M)(87.93M)2.30M(92.93M)12.09M[{"date":"2020-12-31","value":-459.59,"profit":false},{"date":"2021-12-31","value":-727.62,"profit":false},{"date":"2022-12-31","value":19.05,"profit":true},{"date":"2023-12-31","value":-768.99,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)(42.45)(43.20)(3.75)-(1.87)[{"date":"2020-12-31","value":-4245,"profit":false},{"date":"2021-12-31","value":-4320,"profit":false},{"date":"2022-12-31","value":-375,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-187.26,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GYRE
Cash Ratio 0.79
Current Ratio 3.60
Quick Ratio 3.19

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GYRE
ROA (LTM) 5.18%
ROE (LTM) 12.12%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GYRE
Debt Ratio Lower is generally better. Negative is bad. 0.20
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.52

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GYRE
Trailing PE 560.50
Forward PE NM
P/S (TTM) 9.81
P/B 14.50
Price/FCF NM
EV/R 9.53
EV/Ebitda 79.03

FAQs

What is Gyre Therapeutics Inc. share price today?

Gyre Therapeutics Inc. (GYRE) share price today is $8.68

Can Indians buy Gyre Therapeutics Inc. shares?

Yes, Indians can buy shares of Gyre Therapeutics Inc. (GYRE) on Vested. To buy Gyre Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GYRE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Gyre Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Gyre Therapeutics Inc. (GYRE) via the Vested app. You can start investing in Gyre Therapeutics Inc. (GYRE) with a minimum investment of $1.

How to invest in Gyre Therapeutics Inc. shares from India?

You can invest in shares of Gyre Therapeutics Inc. (GYRE) via Vested in three simple steps:

  • Click on Sign Up or Invest in GYRE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Gyre Therapeutics Inc. shares
What is Gyre Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Gyre Therapeutics Inc. (GYRE) is $19. The 52-week low price of Gyre Therapeutics Inc. (GYRE) is $6.11.

What is Gyre Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Gyre Therapeutics Inc. (GYRE) is 560.5

What is Gyre Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Gyre Therapeutics Inc. (GYRE) is 14.50

What is the Market Cap of Gyre Therapeutics Inc.?

The market capitalization of Gyre Therapeutics Inc. (GYRE) is $999.95M

What is Gyre Therapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of Gyre Therapeutics Inc. is GYRE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top